News

Published on 12 Aug 2022 on Zacks via Yahoo Finance

The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex...

Article preview image

For Immediate Release

Chicago, IL – August 12, 2022 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Amgen AMGN, ChemoCentryx CCXI, Mersana Therapeutics, Inc. MRSN, GSK plc GSK and Vertex Pharmaceuticals VRTX.

Here are highlights from Thursday’s Analyst Blog:

Read the rest of the article
NASDAQ.MRSN price evolution
NASDAQ.VRTX price evolution
NASDAQ.AMGN price evolution

Want to become a better investor?

Start tracking your investments with Statfolio

Sign up for free
Related News
Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic...

Mersana Therapeutics Inc (MRSN) reports significant financial improvements and promising clinical...

GuruFocus.com · via Yahoo Finance 14 Nov 2024
SILVERARC CAPITAL MANAGEMENT, LLC Reduces Stake in Mersana Therapeutics Inc

On October 11, 2024, SILVERARC CAPITAL MANAGEMENT, LLC (Trades, Portfolio) executed a significant...

GuruFocus.com · via Yahoo Finance 15 Oct 2024
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Consensus Forecasts Have Become A Little Darker Since Its...

Mersana Therapeutics, Inc. (NASDAQ:MRSN) just released its quarterly report and things are lookin...

Simply Wall St. via Yahoo Finance 10 May 2024
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Call Transcript

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Call Transcript May 9, 2024 Mersana The...

Insider Monkey via Yahoo Finance 10 May 2024
Earnings call: Mersana Therapeutics reports on ADC development progress

Mersana Therapeutics, Inc. (NASDAQ: NASDAQ: MRSN ) has provided updates on its antibody-drug...

Investing.com 1 Mar 2024
Earnings call: Mersana Therapeutics reports on ADC development progress By Investing.com

Mersana Therapeutics, Inc. (NASDAQ: NASDAQ:MRSN) has provided updates on its antibody-drug...

Investing.com 29 Feb 2024
Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript February 28, 2024 Mersa...

Insider Monkey via Yahoo Finance 29 Feb 2024
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday’s...

Shares of Butterfly Network, Inc. BFLY fell sharply during Thursday’s session after the company...

Benzinga 29 Feb 2024
An Intrinsic Calculation For Mersana Therapeutics, Inc. (NASDAQ:MRSN) Suggests It's 26% Undervalued

Key Insights Mersana Therapeutics' estimated fair value is US$6.60 based on 2 Stage Free Cash Flo...

Simply Wall St. via Yahoo Finance 29 Feb 2024
Mersana shares climb as BTIG upgrades to buy with $6 target

Mersana shares climb as BTIG upgrades to buy with $6 target

Investing.com 28 Feb 2024

Copyright Statfolio @ 2025

Social Accounts